Pathology of Parkinson's Disease

ls /home/daytona/workspace/ && ls /home/daytona/skills/docx/

mkdir -p /home/daytona/workspace/pd-pathology && ls /home/daytona/workspace/pd-p…

~/pd-pathology/generate.js

const {
  Document, Packer, Paragraph, TextRun, Table, TableRow, TableCell,
  HeadingLevel, AlignmentType, BorderStyle, WidthType, ShadingType,
  VerticalAlign, PageNumber, Header, Footer, TabStopType, TabStopPosition,
  PageBreak
} = require('docx');
const fs = require('fs');

// ── Colour palette ──────────────────────────────────────────────────────────
const NAVY   = "1F3864";
const BLUE   = "2E74B5";
const LBLUE  = "D6E4F0";
const LGRAY  = "F2F2F2";
const WHITE  = "FFFFFF";
const DARK   = "212121";
const ACCENT = "C0392B";   // red accent for key terms

// ── Helpers ─────────────────────────────────────────────────────────────────
const sp = (sz) => new Paragraph({ children: [new TextRun({ text: "", size: sz })] });

function h1(text) {
  return new Paragraph({
    heading: HeadingLevel.HEADING_1,
    spacing: { before: 360, after: 120 },
    children: [new TextRun({ text, bold: true, size: 32, color: WHITE, font: "Calibri" })],
    shading: { type: ShadingType.SOLID, color: NAVY, fill: NAVY },
    indent: { left: 200, right: 200 },
  });
}

function h2(text) {
  return new Paragraph({
    heading: HeadingLevel.HEADING_2,
    spacing: { before: 280, after: 80 },
    border: { bottom: { style: BorderStyle.SINGLE, size: 6, color: BLUE } },
    children: [new TextRun({ text, bold: true, size: 26, color: NAVY, font: "Calibri" })],
  });
}

function h3(text) {
  return new Paragraph({
    heading: HeadingLevel.HEADING_3,
    spacing: { before: 200, after: 60 },
    children: [new TextRun({ text, bold: true, size: 22, color: BLUE, font: "Calibri" })],
  });
}

function body(text) {
  return new Paragraph({
    spacing: { before: 80, after: 80, line: 276 },
    children: [new TextRun({ text, size: 20, font: "Calibri", color: DARK })],
  });
}

function bullet(text, bold_prefix) {
  const children = [];
  if (bold_prefix) {
    children.push(new TextRun({ text: bold_prefix, bold: true, size: 20, color: DARK, font: "Calibri" }));
    children.push(new TextRun({ text, size: 20, font: "Calibri", color: DARK }));
  } else {
    children.push(new TextRun({ text, size: 20, font: "Calibri", color: DARK }));
  }
  return new Paragraph({
    bullet: { level: 0 },
    spacing: { before: 40, after: 40, line: 260 },
    children,
  });
}

function subbullet(text) {
  return new Paragraph({
    bullet: { level: 1 },
    spacing: { before: 30, after: 30, line: 240 },
    children: [new TextRun({ text, size: 19, font: "Calibri", color: DARK })],
  });
}

function noteBox(text) {
  return new Table({
    width: { size: 100, type: WidthType.PERCENTAGE },
    margins: { top: 60, bottom: 60 },
    rows: [
      new TableRow({
        children: [
          new TableCell({
            shading: { type: ShadingType.SOLID, color: LBLUE, fill: LBLUE },
            borders: {
              top:    { style: BorderStyle.SINGLE, size: 12, color: BLUE },
              bottom: { style: BorderStyle.SINGLE, size: 12, color: BLUE },
              left:   { style: BorderStyle.SINGLE, size: 24, color: NAVY },
              right:  { style: BorderStyle.NONE },
            },
            margins: { top: 80, bottom: 80, left: 160, right: 160 },
            children: [new Paragraph({ children: [new TextRun({ text, size: 19, font: "Calibri", italics: true, color: NAVY })] })],
          }),
        ],
      }),
    ],
  });
}

// ── Generic 2-col table (header row + data rows) ────────────────────────────
function makeTable(headers, rows, colWidths) {
  const headerRow = new TableRow({
    tableHeader: true,
    children: headers.map((h, i) =>
      new TableCell({
        shading: { type: ShadingType.SOLID, color: NAVY, fill: NAVY },
        width: colWidths ? { size: colWidths[i], type: WidthType.PERCENTAGE } : undefined,
        margins: { top: 80, bottom: 80, left: 100, right: 100 },
        children: [new Paragraph({ children: [new TextRun({ text: h, bold: true, size: 18, color: WHITE, font: "Calibri" })] })],
      })
    ),
  });

  const dataRows = rows.map((row, ri) =>
    new TableRow({
      children: row.map((cell, ci) =>
        new TableCell({
          shading: ri % 2 === 0
            ? { type: ShadingType.SOLID, color: LGRAY, fill: LGRAY }
            : { type: ShadingType.SOLID, color: WHITE, fill: WHITE },
          width: colWidths ? { size: colWidths[ci], type: WidthType.PERCENTAGE } : undefined,
          margins: { top: 60, bottom: 60, left: 100, right: 100 },
          children: [new Paragraph({ children: [new TextRun({ text: cell, size: 18, font: "Calibri", color: DARK })] })],
        })
      ),
    })
  );

  return new Table({
    width: { size: 100, type: WidthType.PERCENTAGE },
    rows: [headerRow, ...dataRows],
  });
}

// ── Document ─────────────────────────────────────────────────────────────────
const doc = new Document({
  creator: "Orris Medical Notes",
  title: "Pathology of Parkinson's Disease",
  description: "Summary from Harrison's Principles of Internal Medicine, 22nd Edition",
  styles: {
    default: {
      document: { run: { font: "Calibri", size: 20, color: DARK } },
    },
  },
  sections: [{
    properties: {
      page: {
        margin: { top: 1080, bottom: 1080, left: 1080, right: 1080 },
      },
    },
    headers: {
      default: new Header({
        children: [
          new Paragraph({
            alignment: AlignmentType.RIGHT,
            spacing: { after: 0 },
            border: { bottom: { style: BorderStyle.SINGLE, size: 4, color: BLUE } },
            children: [
              new TextRun({ text: "Pathology of Parkinson's Disease  |  Harrison's 22E", size: 16, color: BLUE, font: "Calibri", italics: true }),
            ],
          }),
        ],
      }),
    },
    footers: {
      default: new Footer({
        children: [
          new Paragraph({
            alignment: AlignmentType.CENTER,
            border: { top: { style: BorderStyle.SINGLE, size: 4, color: BLUE } },
            children: [
              new TextRun({ text: "Harrison's Principles of Internal Medicine, 22nd Edition (2025)  |  Chapter 446  |  Page ", size: 16, color: BLUE, font: "Calibri" }),
              new TextRun({ children: [PageNumber.CURRENT], size: 16, color: BLUE, font: "Calibri" }),
            ],
          }),
        ],
      }),
    },
    children: [

      // ── TITLE BLOCK ──────────────────────────────────────────────────────
      new Paragraph({
        alignment: AlignmentType.CENTER,
        spacing: { before: 0, after: 60 },
        shading: { type: ShadingType.SOLID, color: NAVY, fill: NAVY },
        children: [new TextRun({ text: "PATHOLOGY OF PARKINSON'S DISEASE", bold: true, size: 40, color: WHITE, font: "Calibri" })],
      }),
      new Paragraph({
        alignment: AlignmentType.CENTER,
        spacing: { before: 0, after: 40 },
        shading: { type: ShadingType.SOLID, color: BLUE, fill: BLUE },
        children: [new TextRun({ text: "Harrison's Principles of Internal Medicine, 22nd Edition (2025)", size: 22, color: WHITE, font: "Calibri", italics: true })],
      }),
      new Paragraph({
        alignment: AlignmentType.CENTER,
        spacing: { before: 0, after: 240 },
        shading: { type: ShadingType.SOLID, color: BLUE, fill: BLUE },
        children: [new TextRun({ text: "Chapter 446  ·  Olanow, Schapira & Klein", size: 20, color: WHITE, font: "Calibri" })],
      }),

      // ── 1. OVERVIEW ──────────────────────────────────────────────────────
      h1("1. Overview"),
      sp(40),
      body("Parkinson's disease (PD) is the second most common age-related neurodegenerative disease after Alzheimer's disease. First formally described by James Parkinson in 1817, it affects an estimated 10.8 million people worldwide - a number expected to double within 20 years due to population aging. The mean age of onset is ~60 years, with a lifetime risk of ~3% for men and ~2% for women."),
      sp(40),
      bullet("Clinically defined by: bradykinesia, rest tremor, rigidity, and postural instability"),
      bullet("Non-motor features: autonomic dysfunction, hyposmia, sleep disorders, mood disorders, cognitive impairment/dementia"),
      bullet("Pathological diagnosis requires post-mortem confirmation of Lewy body pathology"),
      sp(60),

      // ── 2. CARDINAL PATHOLOGICAL HALLMARKS ───────────────────────────────
      h1("2. Cardinal Pathological Hallmarks"),
      sp(40),
      body("Three defining neuropathological features characterize PD:"),
      sp(40),
      bullet("Degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNc)", "1.  "),
      bullet("Reduced striatal dopamine", "2.  "),
      bullet("Lewy pathology — intraneuronal α-synuclein inclusions in neuronal cell bodies (Lewy bodies) and axons (Lewy neurites)", "3.  "),
      sp(60),

      noteBox("Key fact: Clinical parkinsonism typically manifests only after >60–80% of SNc dopaminergic neurons have been lost, highlighting the brain's compensatory capacity."),
      sp(80),

      // ── 3. LEWY BODIES ───────────────────────────────────────────────────
      h1("3. Lewy Bodies and Lewy Pathology"),
      sp(40),
      h3("Composition and Appearance"),
      bullet("Round, eosinophilic, intraneuronal cytoplasmic inclusions with a dense core and pale halo on H&E stain"),
      bullet("Composed primarily of aggregated, misfolded alpha (α)-synuclein protein"),
      bullet("Also contain ubiquitin, neurofilaments, and proteasomal elements"),
      bullet("Lewy neurites: α-synuclein aggregates within axons and dendrites"),
      sp(40),
      h3("Distribution Beyond the Substantia Nigra"),
      body("Although the SNc is the primary site, Lewy pathology is widespread:"),
      sp(40),
      makeTable(
        ["Brain Region / Structure", "Neurotransmitter System", "Clinical Consequence"],
        [
          ["Substantia nigra pars compacta (SNc)", "Dopaminergic", "Bradykinesia, tremor, rigidity"],
          ["Nucleus basalis of Meynert (NBM)", "Cholinergic", "Cognitive impairment, hallucinations"],
          ["Locus coeruleus (LC)", "Noradrenergic", "Mood disorders, autonomic dysfunction"],
          ["Raphe nuclei (brainstem)", "Serotonergic", "Depression, anxiety"],
          ["Olfactory bulb", "Multiple", "Hyposmia / anosmia (early symptom)"],
          ["Enteric nervous system", "Autonomic", "Constipation (earliest symptom)"],
          ["Peripheral autonomic NS", "Autonomic", "Orthostatic hypotension, GI/GU dysfunction"],
          ["Cerebral hemispheres / limbic", "Multiple", "Dementia (PDD/DLB)"],
        ],
        [38, 28, 34]
      ),
      sp(80),

      // ── 4. BRAAK STAGING ─────────────────────────────────────────────────
      h1("4. Braak Staging — Spatiotemporal Spread"),
      sp(40),
      body("Pathological studies (Braak et al.) revealed that PD follows a predictable caudorostral progression, beginning peripherally and advancing to the cortex. This staging correlates directly with clinical symptom emergence."),
      sp(40),
      makeTable(
        ["Braak Stage", "Primary Region Affected", "Clinical Correlation"],
        [
          ["Stage 1-2", "Enteric nervous system → Vagus nerve → Lower brainstem (medulla)", "Constipation, hyposmia, REM sleep behavior disorder (RBD)"],
          ["Stage 3-4", "Substantia nigra + basal forebrain", "Motor parkinsonism (bradykinesia, tremor, rigidity)"],
          ["Stage 5-6", "Limbic cortex → Neocortex", "Dementia (PD dementia / DLB)"],
        ],
        [18, 42, 40]
      ),
      sp(40),
      noteBox("Alternative pathway: PD may also originate in the olfactory bulb and spread via olfactory system connections — or start independently in both olfactory and enteric sites simultaneously (dual-hit hypothesis)."),
      sp(80),

      // ── 5. PRION-LIKE PROPAGATION ─────────────────────────────────────────
      h1("5. Prion-like Propagation of α-Synuclein"),
      sp(40),
      body("Evidence from human neuropathology and animal models supports a prion-like mechanism for PD progression:"),
      sp(40),
      bullet("Abnormally folded α-synuclein aggregates act as 'seeds' that template misfolding of normal α-synuclein"),
      bullet("Aggregates propagate transneuronally following established neural connection pathways"),
      bullet("The spread mirrors the anatomical connectivity of the nervous system, not random diffusion"),
      bullet("Pathology from donor neurons has been found in grafted fetal neurons transplanted into PD patients"),
      bullet("This mechanism explains the stereotyped progression described by Braak staging"),
      sp(40),
      noteBox("This is analogous to the spread of misfolded proteins seen in prion diseases (e.g., CJD) and has major implications for disease-modifying therapy targeting α-synuclein propagation."),
      sp(80),

      // ── 6. ALPHA-SYNUCLEIN ───────────────────────────────────────────────
      h1("6. Alpha-Synuclein (α-Synuclein) — The Key Protein"),
      sp(40),
      h3("Normal Function"),
      bullet("Soluble presynaptic protein encoded by the SNCA gene"),
      bullet("Involved in synaptic vesicle trafficking and neurotransmitter release"),
      bullet("Normally exists as an unstructured monomer"),
      sp(40),
      h3("Pathological Behaviour"),
      bullet("Misfolds into beta-sheet-rich oligomers → protofibrils → insoluble amyloid fibrils"),
      bullet("Oligomeric intermediates are considered most neurotoxic"),
      bullet("Disrupts mitochondrial function, ER stress, lysosomal pathways, and synaptic vesicle cycling"),
      bullet("Detected by immunohistochemistry (anti-α-synuclein antibodies) in Lewy bodies"),
      sp(40),
      h3("Genetic Evidence — SNCA Gene Dosage Effect"),
      bullet("Point mutations in SNCA (A53T, A30P, E46K) cause rare familial PD"),
      bullet("SNCA gene duplications → PD with typical features"),
      bullet("SNCA gene triplications → earlier onset, more severe disease with dementia"),
      bullet("More gene copies = higher α-synuclein levels = more severe disease — direct gene dosage effect"),
      sp(80),

      // ── 7. NEUROTRANSMITTER DEFICITS ─────────────────────────────────────
      h1("7. Neurotransmitter Deficits in PD"),
      sp(40),
      makeTable(
        ["System", "Structure Affected", "Deficit", "Clinical Consequence"],
        [
          ["Dopaminergic", "Substantia nigra pars compacta → Striatum (nigrostriatal pathway)", "Severe ↓ striatal dopamine", "Bradykinesia, tremor, rigidity, gait disturbance"],
          ["Cholinergic", "Nucleus basalis of Meynert + Pedunculopontine nucleus", "↓ Acetylcholine", "Cognitive decline, attention deficits, visual hallucinations, fluctuating cognition"],
          ["Noradrenergic", "Locus coeruleus", "↓ Norepinephrine", "Depression, anxiety, orthostatic hypotension, impaired arousal"],
          ["Serotonergic", "Raphe nuclei", "↓ Serotonin", "Depression, anxiety, mood disorders"],
        ],
        [16, 30, 20, 34]
      ),
      sp(80),

      // ── 8. PATHOLOGICAL MECHANISMS ───────────────────────────────────────
      h1("8. Molecular Mechanisms of Neurodegeneration"),
      sp(40),
      h3("1. Protein Misfolding and Impaired Clearance"),
      bullet("Misfolded α-synuclein overwhelms protein degradation systems"),
      bullet("Ubiquitin-proteasome system (UPS) dysfunction — reduces clearance of abnormal proteins"),
      bullet("Autophagy-lysosomal pathway dysfunction — impairs bulk protein clearance"),
      bullet("GBA1 mutations (glucocerebrosidase) impair lysosomal function → accelerated α-synuclein accumulation"),
      sp(40),
      h3("2. Mitochondrial Dysfunction"),
      bullet("Complex I (NADH dehydrogenase) deficiency in the SNc of PD patients"),
      bullet("Reduced ATP production + increased reactive oxygen species (ROS)"),
      bullet("MPTP toxin (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) reproduces parkinsonism by selectively inhibiting Complex I"),
      bullet("PINK1 and Parkin gene mutations (recessive PD) — both regulate mitochondrial quality control and mitophagy"),
      sp(40),
      h3("3. Oxidative Stress"),
      bullet("Dopamine metabolism inherently generates hydrogen peroxide and ROS"),
      bullet("The SNc has high iron content — iron catalyzes hydroxyl radical formation (Fenton reaction)"),
      bullet("SNc neurons have low antioxidant defenses (reduced glutathione)"),
      bullet("Neuromelanin in SNc neurons binds iron, potentially amplifying oxidative damage"),
      sp(40),
      h3("4. Neuroinflammation"),
      bullet("Activated microglia and astrocytes surround degenerating SNc neurons"),
      bullet("Pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) contribute to ongoing neurodegeneration"),
      bullet("Adaptive immune involvement: T-cells are found in the SNc of PD patients"),
      sp(40),
      h3("5. Excitotoxicity"),
      bullet("Loss of SNc neurons → disinhibition of subthalamic nucleus (STN)"),
      bullet("Overactive STN releases excess glutamate onto basal ganglia targets"),
      bullet("NMDA receptor-mediated excitotoxicity contributes to neuronal death"),
      sp(80),

      // ── 9. GENETIC PATHOLOGY ─────────────────────────────────────────────
      h1("9. Genetic Forms and Neuropathological Correlates"),
      sp(40),
      makeTable(
        ["Gene", "Inheritance", "Frequency", "Neuropathology"],
        [
          ["LRRK2 (PARK8)", "Autosomal dominant", "Most common cause of familial PD; ~1–2% of sporadic PD", "Heterogeneous: Lewy bodies in most; some have tau inclusions or no inclusions"],
          ["SNCA (PARK1/4)", "Autosomal dominant", "Rare; point mutations or duplications/triplications", "Classic Lewy body pathology; triplications → severe, widespread LBD"],
          ["GBA1", "Risk factor (heterozygous)", "Most common genetic risk factor (~8–10% PD)", "Typical Lewy body pathology; associated with faster progression and dementia"],
          ["Parkin (PARK2)", "Autosomal recessive", "Most common recessive; early onset", "SNc degeneration often WITHOUT Lewy bodies; pure dopaminergic loss"],
          ["PINK1 (PARK6)", "Autosomal recessive", "Second most common recessive; early onset", "SNc degeneration; mitochondrial dysfunction; may lack Lewy bodies"],
          ["DJ-1 (PARK7)", "Autosomal recessive", "Rare; early onset", "SNc degeneration; mitochondrial/oxidative stress pathway; may lack Lewy bodies"],
        ],
        [15, 18, 25, 42]
      ),
      sp(80),

      // ── 10. ATYPICAL PARKINSONISMS ───────────────────────────────────────
      h1("10. Pathological Comparison with Atypical Parkinsonisms"),
      sp(40),
      makeTable(
        ["Feature", "PD", "MSA", "PSP", "CBS"],
        [
          ["Key protein", "α-Synuclein", "α-Synuclein", "Tau", "Tau"],
          ["Inclusion type", "Lewy bodies / Lewy neurites", "Glial cytoplasmic inclusions (GCIs)", "Neurofibrillary tangles + globose tangles", "Tau deposits + achromatic neurons"],
          ["Cell affected", "Neurons (SNc)", "Oligodendrocytes (glial cells)", "Neurons", "Neurons (cortex + BG)"],
          ["SNc involvement", "Severe", "Present", "Present", "Variable"],
          ["Other regions", "Widespread (brainstem → cortex)", "Striatum, cerebellum, inferior olive", "STN, pallidum, thalamus, brainstem", "Asymmetric cortical atrophy"],
          ["Levodopa response", "Good initially", "Poor / absent", "Poor / absent", "Poor / absent"],
          ["Disease category", "Alpha-synucleinopathy", "Alpha-synucleinopathy", "Tauopathy (4R)", "Tauopathy (4R)"],
        ],
        [20, 20, 20, 20, 20]
      ),
      sp(80),

      // ── 11. SAA / BIOMARKERS ─────────────────────────────────────────────
      h1("11. Pathological Biomarkers — Seed Amplification Assay (SAA)"),
      sp(40),
      body("A major advance in PD diagnosis is the development of the Seed Amplification Assay (SAA), which detects misfolded α-synuclein in biological fluids and enables biological confirmation of Lewy body pathology in living patients."),
      sp(40),
      bullet("Principle: minute amounts of misfolded α-synuclein in CSF or skin biopsies act as seeds that amplify in vitro"),
      bullet("High sensitivity and specificity for PD / DLB"),
      bullet("Now incorporated into the revised International Parkinson's and Movement Disorder Society diagnostic criteria"),
      bullet("Enables earlier diagnosis during the prodromal phase before motor symptoms appear"),
      bullet("RT-QuIC (real-time quaking-induced conversion) is the most widely used SAA platform"),
      sp(60),
      noteBox("The integration of SAA into clinical criteria represents a paradigm shift from purely clinical diagnosis to a biologically-defined diagnosis of Parkinson's disease."),
      sp(80),

      // ── 12. SUMMARY TABLE ────────────────────────────────────────────────
      h1("12. Summary — Prodromal to Advanced Pathology"),
      sp(40),
      makeTable(
        ["Phase", "Pathological Region", "Biomarker / Finding", "Clinical Feature"],
        [
          ["Pre-motor / Prodromal", "Enteric NS, olfactory bulb, dorsal motor nucleus of vagus", "Positive SAA in CSF; abnormal MIBG scintigraphy", "Constipation, hyposmia, RBD, depression"],
          ["Early motor", "SNc (early degeneration, >60% neuron loss)", "Reduced DAT scan signal in putamen; low CSF α-synuclein", "Asymmetric resting tremor, bradykinesia, rigidity"],
          ["Established motor", "SNc (severe degeneration), basal ganglia circuits disrupted", "Marked DAT scan reduction; levodopa response", "Full motor triad + freezing, hypophonia, micrographia"],
          ["Late / Advanced", "Limbic system + neocortex (Braak stages 5–6); NBM, LC", "Cortical atrophy on MRI; cholinergic deficit", "Dementia, psychosis, autonomic failure, falls"],
        ],
        [18, 28, 27, 27]
      ),
      sp(80),

      // ── REFERENCE ────────────────────────────────────────────────────────
      new Paragraph({
        alignment: AlignmentType.CENTER,
        spacing: { before: 240, after: 60 },
        shading: { type: ShadingType.SOLID, color: NAVY, fill: NAVY },
        children: [new TextRun({ text: "REFERENCE", bold: true, size: 22, color: WHITE, font: "Calibri" })],
      }),
      new Paragraph({
        alignment: AlignmentType.CENTER,
        spacing: { before: 80, after: 80 },
        shading: { type: ShadingType.SOLID, color: LBLUE, fill: LBLUE },
        children: [new TextRun({
          text: "Olanow CW, Schapira AHV, Klein C. Parkinson's Disease and Related Disorders. In: Loscalzo J et al., eds. Harrison's Principles of Internal Medicine. 22nd ed. New York: McGraw Hill Medical; 2025. Chapter 446.",
          size: 18, font: "Calibri", italics: true, color: NAVY,
        })],
      }),
    ],
  }],
});

Packer.toBuffer(doc).then(buffer => {
  fs.writeFileSync("/home/daytona/workspace/pd-pathology/PD_Pathology_Harrisons22E.docx", buffer);
  console.log("SUCCESS: Document written.");
}).catch(err => {
  console.error("ERROR:", err);
  process.exit(1);
});

cd /home/daytona/workspace/pd-pathology && node generate.js

python /home/daytona/skills/docx/scripts/office/validate.py /home/daytona/worksp…

ls -lh /home/daytona/workspace/pd-pathology/PD_Pathology_Harrisons22E.docx && py…